Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany.
Liver Int. 2011 Aug;31(7):1021-7. doi: 10.1111/j.1478-3231.2011.02525.x. Epub 2011 Apr 5.
The disparity between the demand for solid organs and the current supply is a growing problem for patients with end-stage liver disease. To overcome organ shortage, extended criteria donor organs are also accepted for liver transplantation.
We here unprecedentedly report the clinical course of patients receiving livers with markedly elevated liver enzymes.
Between November 2007 and December 2010, 15 donor livers with markedly elevated liver enzymes [median aspartate aminotransferase (AST) 1400 (500-7538) U/l, median alanine aminotransferase (ALT) 1026 (308-9179) U/l] were offered to our transplant centre. Based on elaborate judgment, seven of these donor livers were rejected and eight donor livers were transplanted.
All eight transplanted patients showed a liver enzyme peak on the day of surgery (AST 2076 ± 1808 U/l, ALT 1087 ± 833 U/l) and a statistically significant decrease from day 0 to day 7 post-liver transplantation. INR decreased and platelet count increased statistically significantly within 1 week after liver transplantation. The patients were discharged from the hospital 28 ± 11 days after liver transplantation in good clinical condition.
These data demonstrate that using donor livers with markedly elevated liver enzymes may be an acceptable option to expand the donor pool. Universal objective parameters for acceptance should be defined in future studies.
终末期肝病患者对实体器官的需求与当前供应之间的差距是一个日益严重的问题。为了克服器官短缺,也接受扩展标准供体器官进行肝移植。
我们在此前所未有地报告了接受肝脏酶显著升高的患者的临床过程。
2007 年 11 月至 2010 年 12 月,我们的移植中心提供了 15 例肝脏酶显著升高的供体肝脏[中位数天冬氨酸转氨酶(AST)为 1400(500-7538)U/l,中位数丙氨酸转氨酶(ALT)为 1026(308-9179)U/l]。基于精心判断,其中 7 例供体肝脏被拒绝,8 例供体肝脏被移植。
所有 8 例接受移植的患者在手术当天均出现肝酶峰值(AST 2076±1808 U/l,ALT 1087±833 U/l),且从肝移植第 0 天到第 7 天有统计学显著下降。INR 在肝移植后 1 周内显著下降,血小板计数显著增加。患者在肝移植后 28±11 天出院,临床状况良好。
这些数据表明,使用肝脏酶显著升高的供体肝脏可能是扩大供体库的可接受选择。在未来的研究中应定义通用的客观接受标准。